Drug Trial Radar · NCT05972954
OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION)
Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
May 22, 2023
Primary completion
May 14, 2025
Study completion Jul 30, 2025
Sponsor
- Lead sponsor
- Omeicos Therapeutics GmbHIndustry
- Sponsor type
- Industry
- First posted
- Aug 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn about the treatment effects of the investigational new drug OMT-28 in patients with Primary Mitochondrial Disease. The main question\[s\] it aims to answer are: * Is OMT-28 safe and well tolerated in this patient population? * Does OMT-28 reduce Growth Differentiation Factor 15 (GDF-15) and other relevant blood markers of mitochondrial dysfunction and inflammation? * Does OMT-28 improve symptoms of the disease, e.g. fatigue or exercise intolerance? Participants will be asked to participate in 6 study visits at an experienced clinical center, including physical examinations and exercise tests, and take the study medication regularly once per day according to the protocol. Researchers will compare for every participant the results after 3 months and 6 months of treatment with a preceding 3 month period of standard care treatment to investigate the effects of OMT-28 on clinical parameters and a number of blood parameters.
Conditions
- Primary Mitochondrial Disease
Interventions
OMT-28Drug
once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Responder rateTime frame: 12 weeks treatment vs. 12 weeks baseline
- Number of Treatment Emergent Adverse Events (TEAE)Time frame: up to 28 weeks
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
Universitätsklinikum Bonn, Sektion Neuromuskuläre Erkrankungen, Klinik und Poliklinik für Neurologie, Venusberg-Campus 1, Gebäude 80, NPP
Bonn, Germany
Medizinisch Fakultät der Martin-Luther-Universität Halle-Wittenberg Universitätsklinik und Poliklinik für Neurologie Universitätsklinikum , Ernst-Grube-Str. 40
Halle, Germany
Friedrich-Baur-Institut an der Neurologischen Klinik und Poliklinik, Klinikum der Universität München, Ludwig-Maximilians-Universität (LMU Klinikum), Ziemssenstr. 1a
Munich, Germany
IRCCS Institute of Neurological Science of Bologna, University of Bologna, Department of Biomedical and Neuromotor Science (DIBINEM), Ospedale Bellaria Via Altura, 3
Bologna, Italy
U.O.C. di Neurologia e Malattie Neuromuscolari
Messina, Italy
IRCCS Istituto Neurologico Carlo Besta, SC Servizio Di Medicina Di Laboratorio - Genetica Medica E Neurogenetica, Via Celoria 11
Milan, Italy
Azienda Ospedaliero Universitaria Pisana, P.O. Santa Chiara, U.O. Neurologia, Edificio 13, Via Roma 67
Pisa, Italy
UOC di neurofisiopatologia
Roma, Italy
Radboud University Nijmegen Medical Centre
Nijmegen, Gelderland, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.